|Year : 2019 | Volume
| Issue : 7 | Page : 1226-1229
Molecular characterization of a rare phenotype of X-linked retinoschisis with angle-closure glaucoma
Harathy Selvan1, Anshul Sharma2, Shweta Birla2, Shikha Gupta1, Bindu I Somarajan1, Viney Gupta1, Arundhati Sharma2
1 Dr Rajendra Prasad Centre for Ophthalmic Sciences, Laboratory of Cuto-Molecular Genetics, All India Institute of Medical Sciences, New Delhi, India
2 Department of Anatomy, Laboratory of Cuto-Molecular Genetics, All India Institute of Medical Sciences, New Delhi, India
|Date of Submission||22-Aug-2018|
|Date of Acceptance||12-Mar-2019|
|Date of Web Publication||25-Jun-2019|
Dr. Harathy Selvan
Room No. 494, 4th Floor, Dr.Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi - 110 029
Source of Support: None, Conflict of Interest: None
A 11-year-old boy presented with complaints of blurred vision and on evaluation was found to have X-linked retinoschisis (XLRS) with angle-closure glaucoma. Clinical and genetic evaluation of first-degree family members was done. His brother had a milder form of XLRS with shallow anterior chamber. Topical dorzolamide 2% and timolol 0.5% were used to control intraocular pressure. Genetic analysis revealed a novel three base pair deleterious mutation (c. 375_377 del AGA) in exon-5 of the RS1 gene in three members of the family.
Keywords: Angle-closure glaucoma, dorzolamide, foveoschisis, RS1 mutation, X-linked retinoschisis
|How to cite this article:|
Selvan H, Sharma A, Birla S, Gupta S, Somarajan BI, Gupta V, Sharma A. Molecular characterization of a rare phenotype of X-linked retinoschisis with angle-closure glaucoma. Indian J Ophthalmol 2019;67:1226-9
|How to cite this URL:|
Selvan H, Sharma A, Birla S, Gupta S, Somarajan BI, Gupta V, Sharma A. Molecular characterization of a rare phenotype of X-linked retinoschisis with angle-closure glaucoma. Indian J Ophthalmol [serial online] 2019 [cited 2020 Apr 5];67:1226-9. Available from: http://www.ijo.in/text.asp?2019/67/7/1226/260977
Harathy Selvan and Anshul Sharma: Both authors contributed equally
X-linked retinoschisis (XLRS) is an inherited disorder characterized by splitting within the neurosensory retina. It is usually detected at school age. According to Deutman, foveoschisis is characteristic of XLRS and occurs in 98%–100% of them, while Kellner et al. reported that though macular changes may be seen in all, the typical foveoschisis is found only in 70%. Peripheral retinoschisis is seen in up to 50% of the patients., Other ocular manifestations of XLRS include hypermetropia, strabismus, neovascularization, vitreous veils, vitreous hemorrhage, retinal detachment, etc. More than 196 mutations of RS1 gene in chromosome Xp22.2 have been shown to contribute to XLRS. The disease phenotype is highly variable in that even patients of same genotype manifest different severities. The glaucoma usually associated with XLRS is the neovascular type. We report here an uncommon association of XLRS with angle-closure glaucoma.
| Case Report|| |
A 11-year-old boy presented with slowly progressive decrease in vision both eyes (BE) over 1 year. On examination, his visual acuity (VA) was 6/18 BE with no further improvement on refraction (RE + 1DC@180° and LE-1DC@75°). Baseline intraocular pressure (IOP) was 30 and 32 mmHg, pachymetry 484 and 490μ in right eye (RE) and left eye (LE), respectively. Slit-lamp biomicroscopy showed shallow anterior chamber (Van-Herick II) and occludable angles on gonioscopy BE. A +90D fundus examination revealed cup-disc ratio (CDR) of 0.7 and 0.8:1 in RE and LE, respectively, with spoke-wheel appearance of macula BE. Indirect ophthalmoscopic examination revealed bilateral inferotemporal retinoschisis [Figure 1]. Macular optical coherence tomography (OCT) showed multilevel foveoschisis in BE with central macular thickness (CMT) of 406 and 337μ RE and LE, respectively [Figure 2]. Biometry was done to rule out lens-induced angle-closure, which revealed the axial lengths (AL) to be 21.43 and 22 mm, lens thicknesses 3.30 and 3.51 mm, anterior chamber depths 2.96 and 2.61 mm in RE and LE, respectively.
|Figure 1: Images of the proband of right eye. (a) Fundus photograph showing glaucomatous disc of cup-disc ratio 0.7:1. (b) Spoke-wheel appearance of macula (foveoschisis). (c) Inferotemporal peripheral retinoschisis|
Click here to view
|Figure 2: Macular OCT, (a and b) showing baseline multilevel foveoschitic cavities in RE and LE, respectively. (c and d) showing significant decrease in schitic cavities and central macular thickness of RE and LE respectively, after 6 weeks of topical dorzolamide therapy|
Click here to view
The child was started on a combination of topical dorzolamide and timolol maleate. After 1-week, his IOP was 12 mmHg BE. The family members of the patient were screened. His elder sibling (13-year-old male) had an unaided VA of 6/6 RE and 6/60 LE with no further improvement on refraction. Examination of the sibling showed BE shallow AC with occludable angles and peripheral retinoschisis, with macular spokes in LE. However, his IOP was 14 mmHg and CDR 0.3:1 with healthy rim BE. His refraction showed RE emmetropia and LE + 3DS. His AL was 22.53 and 21.18 mm, pachymetry 580 and 579μ in RE and LE, respectively. Macular OCT showed very few paracentral schitic cavities in LE, and CMT 332μ, not justifying the visual loss. Hence, a diagnosis of BE XLRS and angle-closure suspect with LE anisometropic amblyopia was made. Ocular examination of the father also showed LE anisometropic amblyopia, while the mother's eyes were normal.
After 6 weeks of medication, the proband's IOP was 12 mmHg BE and CMT decreased to 249 and 243μ in RE and LE respectively with significant collapse of the schitic cavities [Figure 2]. However, there was no change in best corrected VA.
An informed consent was taken from the parents and peripheral venous blood sample was drawn for molecular investigations from both children and parents. Genomic DNA was extracted using standard salting-out protocol and subjected to polymerase chain reaction amplification of RS1 gene using 70–100 ng DNA, 1.25mM MgCl2, 0.25 mM of each of the dNTPs (Invitrogen), 5 μM of each primer and 0.5 units of Taq Polymerase (Invitrogen) in 25 μl volume mixture using thermocycler ABI 9700 (Applied Biosystems).
All the amplified products were purified using Qiagen kits (Qiagen, GmbH), sequenced using BigDye Terminator Mix version 3.1 (Applied Biosystems), and analyzed on ABI-3100 Genetic Analyzer. The nucleotide sequences were compared with the published cDNA sequences of RS1 (GenBank accession number ENSG00000102104) gene.
Direct sequencing of RS1 gene revealed a novel three base pair deletion (c. 375_377 del AGA) in exon-5 in three family members [Figure 3]. The proband and his brother were hemizygous, while their mother was heterozygous for the mutation. The father had a normal genotype. Assessment for pathogenicity using MutationT@ster predicted the mutation to be deleterious. Structural analysis revealed that the 'AGA' deletion led to disruption of the downstream codon, resulting in protein lacking amino acid 'D' at position 126. Sequence alignments of RS1 revealed the D residue to be highly conserved over several species [Figure 3].
|Figure 3: In silico and structural analysis of RS1 protein (a). Homozygous deletion of nucleotides 'AGA' leading to frameshift disrupting aspartic acid codon thereby deleting 'D' from mutated protein. (b). Multiple sequence alignment of RS1 nucleotide sequences in different species showing conservation of 'D' (highlighted) in all orthologs (c, d and e) show computational analysis of RS1 delAGA mutation. (c). Normal protein monomer showing amino acid 'D' (blue) with disrupted codon due to AGA deletion. (d). Mutant protein with absent 'D' amino acid. (e). Superimposed structural analysis of normal and mutant protein|
Click here to view
| Discussion|| |
Peripapillary retinoschisis in acquired optic nerve head (ONH) cupping has been shown in a spectrum of glaucoma patients. Advanced glaucomas have also been associated with macular schisis., The pathophysiology attributed is liquid vitreous seeping through holes in the thin tissue overlying ONH cup, causing peripapillary retinal edema, and subsequently schisis. This fluid flow is accentuated by increased IOP., However, the above mechanism was not the cause of foveoschisis in our patient. The sibling also showed foveoschisis but did not have glaucoma. Likewise, the peripheral retinoschisis in the proband could not have been due to glaucoma.
The presence of occludable angles and angle-closure glaucoma at such a young age seems to be genetically linked to RS1 mutations. Low et al. reported a case of refractory angle closure glaucoma with XLRS in a 39-year-old man, that was treated by lens extraction. Sonmez and Ozcan described a case of foveoschisis with angle-closure glaucoma secondary to nanophthalmos (axial length ≈ 16 mm) and cystinosis. The anterior chamber depth, lens thickness, and axial length in our patient did not justify lens-induced glaucoma or nanophthalmos. Huang et al. described recurrent glaucoma in a case of retinoschisis with R102W RS1 mutation. However, the authors did not characterize the nature of the glaucoma in their patient. Pimenides et al. found that there was no correlation between disease severity and RS1 mutation type. Even within families, the severity varied and different patients of similar age and same mutation had varied phenotypic characteristics.
Topical carbonic anhydrase inhibitors like dorzolamide 2% have been shown to be beneficial in cases of XLRS, causing significant reduction in foveal cystic cavities. Our proband, after 6 weeks of dorzolamide usage, showed significant reduction in the central macular thickness of both eyes (RE 39% and LE 29%), which sustained until last follow-up.
| Conclusion|| |
In conclusion, this case highlights the unusual association of XLRS with angle-closure glaucoma underscored by a novel RS1 deleterious mutation.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
George ND, Yates JR, Moore AT. X linked retinoschisis. Br J Ophthalmol 1995;79:697-702.
Deutman A. Sex-linked juvenile retinoschisis. In: The Hereditary Dystrophies of the Posterior Pole of the Eye. Assen, Netherlands: Van Gorcum; 1971. p. 48-98.
Kellner U, Brümmer S, Foerster MH, Wessing A. X-linked congenital retinoschisis. Graefes Arch Clin Exp Ophthalmol 1990;228:432-7.
Kim DY, Mukai S. X-linked juvenile retinoschisis (XLRS): A review of genotype-phenotype relationships. SeminOphthalmol 2013;28:392-6.
Zuo C, Chen C, Xing Y, Du L. Neovascular glaucoma in a patient with X-linked juvenile retinoschisis. Yan KeXue Bao 2005;21:140-1, 151.
Bayraktar S, Cebeci Z, Kabaalioglu M, Ciloglu S, Kir N, Izgi B. Peripapillary retinoschisis in glaucoma patients. J Ophthalmol 2016;2016:e1612720.
Zumbro DS, Jampol LM, Folk JC, Olivier MMG, Anderson-Nelson S. Macular schisis and detachment associated with presumed acquired enlarged optic nerve head cups. Am J Ophthalmol 2007;144:70-4.
Hollander DA, Barricks ME, Duncan JL, Irvine AR. Macular schisis detachment associated with angle-closure glaucoma. Arch Ophthalmol Chic Ill 1960 2005;123:270-2.
Low S, Mohamed R, Ting M, Webster AR, Garway-Heath DF. The treatment of refractory angle-closure glaucoma in a patient with X-linked juvenile retinoschisis. Ophthalmic Genet 2018;39:625-7.
Sonmez K, Ozcan PY. Angle-closure glaucoma in a patient with the nanophthalmos-ocular cystinosis-foveoschisis-pigmentary retinal dystrophy complex. BMC Ophthalmol 2012;12:23.
Huang XF, Tu CS, Xing DJ, Gan DK, Xu GZ, Jin ZB. R102W mutation in the RS1 gene responsible for retinoschisis and recurrent glaucoma. Int J Ophthalmol 2014;7:169-72.
Pimenides D, George N, Yates J, Bradshaw K, Roberts S, Moore A, et al
. X-linked retinoschisis: Clinical phenotype and RS1 genotype in 86 UK patients. J Med Genet 2005;42:e35.
Genead MA, Fishman GA, Walia S. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with X-linked retinoschisis. Arch Ophthalmol Chic Ill 1960 2010;128:190-7.
[Figure 1], [Figure 2], [Figure 3]